Infertility Drugs and Devices Market, By Type (Infertility Drugs (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), Infertility Devices (Equipment, Accessories)), By Gender (Male, Female), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023

Code : CMI4122

Pages :165

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Infertility Drugs and Devices Market: Key Developments

In January 2020, Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany, and Bayer AG, a multinational pharmaceutical and biotechnology company in Germany, announced the expansion of its partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).

In September 2022, NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for chronic liver and related metabolic diseases and Dong-A ST Co., Ltd., a pharmaceutical company, announced that they have entered into a conditional exclusive license agreement for fertile to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of infertility.

In June 2022, Mankind Pharma, a pharmaceutical company in India, developed and launched a generic version of Dydrogestrone tablets for the treatment of patients’ pregnancy-related complications in India. This drug was an equivalent version of Abbott Duphaston tablets. This launch was expected to drive infertility treatment market.